Brief: Unity Biotechnology announces positive data in Phase 2 behold study of UBX1325 in patients with diabetic macular edema
12/08/2022 12:20
Aug 12 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY ANNOUNCES POSITIVE DATA IN PHASE 2
BEHOLD
STUDY OF UBX1325 IN PATIENTS WITH DIABETIC MACULAR EDEMA
* UNITY BIOTECHNOLOGY INC - UBX1325 TREATMENT ALSO
STABILIZED
RETINAL STRUCTURE, AS MEASURED BY CENTRAL SUBFIELD THICKNESS
(CST) AT 12- AND 18-WEEKS
* UNITY - SINGLE INJECTION OF UBX1325 LED TO PROGRESSIVE,
STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL IMPROVEMENT IN
MEAN BCVA AT 12- AND 18-WEEKS
* UNITY BIOTECHNOLOGY INC - TREATMENT EFFECT WAS SEEN IN A
PATIENT
POPULATION WITH VISUAL ACUITY DEFICITS AND RESIDUAL RETINAL
FLUID
* UNITY BIOTECHNOLOGY INC - UBX1325 DEMONSTRATED A FAVORABLE
SAFETY AND TOLERABILITY PROFILE
Source text for Eikon: ID:nGNXbtNN6m
Further company coverage: UBX.O
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force